Published online March 27, 2006
PEDIATRICS Vol. 117 No. 4 April 2006, pp. e793-e795 (doi:10.1542/peds.2005-1705)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wit, J.M.
Right arrow Articles by de Zegher, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wit, J.M.
Right arrow Articles by de Zegher, F.
Related Collections
Right arrow Premature & Newborn

Preterm Growth Restraint: A Paradigm That Unifies Intrauterine Growth Retardation and Preterm Extrauterine Growth Retardation and Has Implications for the Small-for-Gestational-Age Indication in Growth Hormone Therapy

J.M. Wit, MD, PhDa, M.J.J. Finken, MDa, M. Rijken, MDa and F. de Zegher, MD, PhDb

a Department of Pediatrics, Leiden University Medical Center, Leiden, Netherlands
b Department of Pediatrics, University of Louvain, Louvain, Belgium

Abbreviations: SGA, small for gestational age • IUGR, intrauterine growth retardation • EUGR, extrauterine growth retardation • GH, growth hormone • PGR, preterm growth restraint

The first 20% of the full text of this article appears below.

Small for gestational age (SGA) is defined as a birth weight and/or length >2 SDs below the gender-specific population reference mean for gestational age. However, there is confusion about various aspects of this term, as recently discussed.1,2 The term "intrauterine growth retardation" (IUGR) is often used for the same condition but preferably should be restricted to poor growth during pregnancy according to intrauterine growth diagrams used in obstetrics.3 SGA after a normal duration of gestation (37–42 weeks) is usually followed by rapid growth after birth (catch-up growth). It has been demonstrated that almost 90% of term SGA infants catch up in height in the first 2 years of postnatal life.4,5

On average, the human male has a birth length of 51 cm after term gestation and a final height, in the Netherlands, of 184 cm. Thus, in the 9 months before birth, he has reached almost 30% of his adult height potential. Fetal length velocity at midgestation is >10-fold higher than pubertal peak height velocity (Fig 1).


Figure Removed (Available Only in the Full Text)
View larger version (10K):
[in this window]
[in a new window]
 
FIGURE 1 Normal length/height velocity from conception to adulthood (boys). Fetal length velocity reaches its maximum during midgestation, ~10 cm/month, and declines to ~35 cm/year around birth. In comparison, the median for peak height velocity during puberty is 9.42 cm/year. Postnatal height velocity (median values) is according to Dutch reference values.13

 
Thus, very preterm infants are exposed to extrauterine life during a period that normally is characterized by rapid intrauterine growth. To survive, their energy expenditure shifts from growth-promoting actions to survival strategies to cope with the increased requirements of unintended postnatal life. Extrauterine growth retardation (EUGR) is often the result. Preterm infants whose mothers suffered . . . [Full Text of this Article]

Address correspondence to J.M. Wit, MD, PhD, Department of Pediatrics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Netherlands. E-mail: j.m.wit@lumc.nl




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
J Rotteveel, M M van Weissenbruch, and H A Delemarre-Van de Waal
Decreased insulin sensitivity in small for gestational age males treated with GH and preterm untreated males: a study in young adults.
Eur. J. Endocrinol., June 1, 2008; 158(6): 899 - 904.
[Abstract] [Full Text] [PDF]